Raphael Pharmaceutical Inc. (RAPH)
OTCMKTS · Delayed Price · Currency is USD
1.400
0.00 (0.00%)
At close: Jul 28, 2026
Raphael Pharmaceutical Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0 | 0.05 | 0.02 | 0.23 | 0.29 | 0.15 |
Cash & Short-Term Investments | 0 | 0.05 | 0.02 | 0.23 | 0.29 | 0.15 |
Cash Growth | -95.00% | 136.84% | -91.74% | -20.14% | 88.23% | 61.05% |
Other Receivables | - | 0 | 0 | 0.01 | 0.04 | 0.09 |
Receivables | - | 0 | 0 | 0.01 | 0.04 | 0.09 |
Prepaid Expenses | - | 0 | 0 | - | 0.01 | 0.18 |
Total Current Assets | 0.01 | 0.05 | 0.03 | 0.24 | 0.33 | 0.42 |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | - |
Total Assets | 0.01 | 0.05 | 0.03 | 0.24 | 0.33 | 0.42 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.54 | 0.16 | 0.13 | 0.07 | 0.07 | 0.11 |
Accrued Expenses | 1.31 | 1.29 | 0.6 | 0.06 | 0.16 | 0.19 |
Short-Term Debt | 0.04 | 0.03 | 0.04 | - | - | - |
Total Current Liabilities | 1.89 | 1.49 | 0.77 | 0.13 | 0.23 | 0.29 |
Total Liabilities | 1.89 | 1.49 | 0.77 | 0.13 | 0.23 | 0.29 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.2 | 0.2 | 0.19 | 0.19 | 0.16 | 0.13 |
Additional Paid-In Capital | 8.53 | 8.53 | 7.96 | 7.39 | 5.98 | 2.67 |
Retained Earnings | -10.62 | -10.17 | -8.89 | -7.37 | -6.03 | -2.67 |
Comprehensive Income & Other | - | - | - | -0.1 | - | - |
Shareholders' Equity | -1.89 | -1.43 | -0.74 | 0.11 | 0.11 | 0.13 |
Total Liabilities & Equity | 0.01 | 0.05 | 0.03 | 0.24 | 0.33 | 0.42 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.04 | 0.03 | 0.04 | - | - | - |
Net Cash (Debt) | -0.04 | 0.01 | -0.02 | 0.23 | 0.29 | 0.15 |
Net Cash Growth | - | - | - | -20.14% | 88.23% | - |
Net Cash Per Share | -0.00 | 0.00 | -0.00 | 0.01 | 0.02 | 0.01 |
Filing Date Shares Outstanding | 20.18 | 20.18 | 19.63 | 18.66 | 16.14 | 12.97 |
Total Common Shares Outstanding | 20.18 | 20.18 | 18.7 | 18.5 | 15.62 | 12.97 |
Working Capital | -1.89 | -1.44 | -0.74 | 0.11 | 0.1 | 0.13 |
Book Value Per Share | -0.09 | -0.07 | -0.04 | 0.01 | 0.01 | 0.01 |
Tangible Book Value | -1.89 | -1.43 | -0.74 | 0.11 | 0.11 | 0.13 |
Tangible Book Value Per Share | -0.09 | -0.07 | -0.04 | 0.01 | 0.01 | 0.01 |